IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured In A Presentation At BISICON 2023 In India
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical Ltd. (NASDAQ:ICCM) announced its participation in the 10th Annual Conference of the Breast Imaging Society of India (BISICON 2023) where its ProSense® System was featured. The system, a minimally-invasive cryoablation technology that destroys tumors by freezing, was used to perform India's first breast cryoablation procedure in June 2023. The ICE3 trial results of ProSense® showed a 96.91% recurrence free rate, 100% safety, and 100% doctor and patient satisfaction. The trial is expected to be finalized in Q1 2024.
October 30, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure's ProSense® System was featured at a major conference and has shown promising results in its ICE3 trial. This could potentially increase the company's market share and stock value.
The positive results from the ICE3 trial and the exposure at the BISICON 2023 conference could potentially increase the demand for IceCure's ProSense® System. This could lead to increased revenues for the company and a potential increase in its stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100